Ceftezole
- J01DB12 (WHO)
- (6R,7R)-8-oxo-7-{[2-(tetrazol-1-yl)acetyl]amino}-
3-(1,3,4-thiadiazol-2-ylsulfanylmethyl)-5-thia-
1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
- 26973-24-0
- 65755
- 59178 Y
- 2Z86SYP11W
- D07656 Y
- ChEMBL1697829
- DTXSID0022771
- Interactive image
- O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)Cn3nnnc3)CSc4nncs4)C(=O)O
- InChI=1S/C13H12N8O4S3/c22-7(1-20-4-14-18-19-20)16-8-10(23)21-9(12(24)25)6(2-26-11(8)21)3-27-13-17-15-5-28-13/h4-5,8,11H,1-3H2,(H,16,22)(H,24,25)/t8-,11-/m1/s1 Y
- Key:DZMVCVMFETWNIU-LDYMZIIASA-N Y
Ceftezole (or ceftezol) is a semisynthetic first-generation cephalosporin antibiotic.[1]
Ceftezole binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.[citation needed]
Ceftezole is having (1,3,4-thiadiazol-2-ylsulfanyl)methyl and [2-(1H-tetrazol-1-yl)acetamido side groups located at positions 3 and 7 respectively. It is a cephalosporin and a member of thiadiazoles.[citation needed]
References
- ^ Berger SA (2021). "Ceftezole". GIDEON Guide to Antimicrobial Agents. Los Angeles: Gideon Informatics, Incorporated. p. 301. ISBN 978-1-4988-2958-8.
Note
- This article incorporates public domain material from Ceftezole (compound). National Center for Biotechnology Information - the National Library of Medicine - PubChem®.
External links
- Media related to Ceftezole at Wikimedia Commons
- v
- t
- e
(inhibit synthesis
of peptidoglycan
layer of bacterial
cell wall by binding
to and inhibiting
PBPs, a group of
D-alanyl-D-alanine
transpeptidases)
Glycopeptides Lipoglycopeptides |
|
---|---|
Lipopeptides |
|
Polymyxins |
|
Other |
|
- Inhibit PG subunit synthesis and transport: NAM synthesis inhibition (Fosfomycin)
- DADAL/AR inhibitors (Cycloserine)
- bactoprenol inhibitors (Bacitracin)
- Hydrolyze NAM-NAG
- Tyrothricin
- Isoniazid#
- Teixobactin
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e